BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Celltrion Launches STEQEYMA®, a Biosimilar to STELARA®, in the U.S. at an 85% Lower WAC List Price

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as the reference produc...

March 13, 2025 | News

Celltrion’s OMLYCLO® Becomes First FDA-Approved Interchangeable Biosimilar to XOLAIR®

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for intercha...

March 10, 2025 | News

Celltrion Secures FDA Approval for STOBOCLO® and OSENVELT® as Biosimilars to PROLIA® and XGEVA®

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA®&nbs...

March 05, 2025 | News

SmithRx Expands Connect 360 Autoimmune Program Adding Stelara Biosimilars and Partnering with Costco Specialty Pharmacy

SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), announced a major expansion to its Connect 360 Autoimmune Program, ...

March 03, 2025 | News

South Korea’s Celltrion Secures EU Approval for Three Biosimilar Products, Expanding Its Portfolio to 11 by 2025

Celltrion gains simultaneous regulatory approval of two monoclonal antibody biosimilars across three treatments – Eydenzelt® (aflibe...

February 19, 2025 | News

Celltrion Secures FDA Approval for AVTOZMA® Biosimilar to ACTEMRA® in IV and SC Formulations

AVTOZMA® will be available as both intravenous (IV) and subcutaneous (SC) formulations with the same formulations and dosages as the reference p...

January 31, 2025 | News

Taiwan’s Taikang Biotech Joins Forces with Mitsubishi Gas Chemical and Taiwan Sugar Alliance to Propel SPD8 Biosimilar Globally

Taikang Biotech (6589), Mitsubishi Gas Chemical Co., Ltd. (MGC), and the Taiwan Sugar Association (4168) have entered into a strategic tripartite agreement...

December 26, 2024 | News

CHMP Endorses Celltrion’s Biosimilars Eydenzelt Stoboclo Osenvelt and Avtozma for Expanded Access to Biologic Treatments

The Committee for Medicinal Products for Human Use (CHMP) adopts positive opinions for Celltrion’s three biosimilar candidates – Eydenz...

December 16, 2024 | News

GCCL Launches R&D Division to Bolster Biosimilar and Clinical Trial Analysis Services

Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockb...

July 17, 2024 | News

Biocon Biologics Teams Up with Sandoz Australia for Biosimilar Trastuzumab and Bevacizumab

Under the agreement, Sandoz will distribute the Biocon Biologics' brands, OGIVRI® (bTrastuzumab) and ABEVMY® (bBevacizumab), and facilita...

February 09, 2024 | News

Mabxience and Abbott Forge Strategic Deal to Expand Biosimilars Access in Emerging Markets

Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia and Middle East and Africa mAbxience Holdi...

September 21, 2023 | News

Celltrion Celebrates a Decade of Biosimilar Innovation in Europe

Marking 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal antibody biosimilar infliximab, for all indication...

September 11, 2023 | News

Mabwell's Biosimilar Denosumab solution approved by NMPA for osteoporosis treatment

Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (...

April 04, 2023 | News

Altos Biologics Enrolls Patients in Global Phase 3 Trial for Eylea® Biosimilar in Neovascular Age-related Macular Degeneration.

Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) clinical development and licensing-out disc...

February 23, 2023 | News

Stay Connected